Treatment (Tx) patterns, efficacy and safety of eribulin for advanced and heavily pretreated breast cancer (ABC): A single-center, real-world study.

Abstract

e13118 Background: We evaluated the Tx patterns, efficacy and safety of eribulin for heavily pretreated ABC in real-world practice. Methods: Patients (pts) with ABC who had progression on anthracycline/taxane Tx and received eribulin (1.4 mg/m2 IV on Days 1 and 8 of a 21-day cycle) between April 2020 and August 2022 were enrolled. Response was evaluated using RECIST v1.1. Results: 73 pts were enrolled. Median (range) age was 54 (30–79) years; 78.1% had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0–1, and pts had a median of 3 prior lines of chemotherapy. 69.9% of pts had Ki67 >30% and 52.1% had HR+/HER2− disease. 90.4% of pts had visceral metastasis. Eribulin was monotherapy in 28.8% of pts, and combined with bevacizumab, capecitabine, bevacizumab + capecitabine, and anti-HER2 agents in 28.8%, 10.9%, 4.1%, and 27.4%, respectively. The objective response rate was 24.7%; disease control rate was 75.3%. Median progression-free survival (PFS) overall was 6.0 (95% CI, [3.8–8.2]) months (mo). Univariate analysis indicated pts with HER2+ disease had longer PFS than pts with HR+/HER2− or triple-negative BC (median, 8.0, 6.0, and 3.0 mo, respectively; P = 0.049). Pts with Ki67 expression ≤30% had longer PFS than pts with Ki67 >30% (median, 8.0 vs. 4.0 mo; P = 0.024). Pts with late relapse (disease-free survival [DFS] >24 mo) had longer PFS than pts with early recurrence (DFS 6–24 mo) or de novo disease (DFS <6 mo; median PFS, 9.0, 4.5, and 3.6 mo, respectively; P = 0.026). Among 38 pts with HR+/HER2− ABC, pts who received eribulin plus capecitabine had longer PFS than pts who received eribulin monotherapy (median 11.4 vs. 4.0 mo, P = 0.021). Among the 18 pts with a partial response, median PFS was 9.5 mo. Multivariate analysis indicated line of Tx predicted PFS; pts who received eribulin as line 1–3 had longer PFS than pts who received eribulin as line >3 (HR=0.42 [95% CI, 0.19–0.93]; P = 0.034). The most common adverse events were leukopenia (43.2%), anemia (37.9%), and neutropenia (37.8%). Neurotoxicity was rare (2.7%). Conclusions: In this single-center study of pts with heavily pre-treated ABC in China, eribulin Tx resulted in favorable PFS irrespective of molecular subtype, with a manageable safety profile. In pts with a large tumor burden and a good PS, eribulin-based combinations may further improve outcomes. [Table: see text]